129 related articles for article (PubMed ID: 6105768)
21. Clinical evidence for multiple dopamine receptors in man.
Meltzer HY
Commun Psychopharmacol; 1979; 3(6):457-70. PubMed ID: 44694
[No Abstract] [Full Text] [Related]
22. Further evidence for the existence of multiple receptors for dopamine in the central nervous system.
Iversen LL; Quik M; Emson PC; Dowling JE; Watling KJ
Adv Biochem Psychopharmacol; 1980; 21():193-202. PubMed ID: 6103646
[No Abstract] [Full Text] [Related]
23. Site-specific blockade of dopamine receptors by neuroleptic agents in human brain.
Borison RL; Fields JZ; Diamond BI
Neuropharmacology; 1981 Dec; 20(12B):1321-2. PubMed ID: 6119643
[No Abstract] [Full Text] [Related]
24. Transient alterations in neurotransmitter activity in the caudate nucleus of rat brain after a high dose of ionizing radiation.
Hunt WA; Dalton TK; Darden JH
Radiat Res; 1979 Dec; 80(3):556-62. PubMed ID: 42108
[No Abstract] [Full Text] [Related]
25. Optic tectum adenylate cyclase activity from goldfish (Carassius auratus) as a model to assess dopamine receptor agonists and antagonists.
De Sarro A; De Gori N; Urna G; Pujia A; Nistico' G
Res Commun Chem Pathol Pharmacol; 1983 Feb; 39(2):241-9. PubMed ID: 6133329
[TBL] [Abstract][Full Text] [Related]
26. Chronic haloperidol does not increase specific dopamine receptor binding in rat frontal cortex.
Meller E; Bohmaker K; Rosengarten H; Friedhoff AJ
Res Commun Chem Pathol Pharmacol; 1982 Sep; 37(3):323-32. PubMed ID: 7178646
[TBL] [Abstract][Full Text] [Related]
27. Chronic neuroleptic treatment and dopamine receptor regulation.
Creese I; Snyder SH
Adv Biochem Psychopharmacol; 1980; 24():89-94. PubMed ID: 6105809
[No Abstract] [Full Text] [Related]
28. Tardive dyskinesia: a biological appraoch.
Barbaccia ML; Trabucchi M
Prog Clin Biol Res; 1980; 39():181-93. PubMed ID: 6105670
[No Abstract] [Full Text] [Related]
29. Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system. II. Comparison with dopamine- and isoproterenol-sensitive adenylate cyclases in rat brain.
Enjalbert A; Hamon M; Bourgoin S; Bockaert J
Mol Pharmacol; 1978 Jan; 14(1):11-23. PubMed ID: 24167
[No Abstract] [Full Text] [Related]
30. Pre- and postsynaptic mechanisms in haloperidol-induced sensitization to dopaminergic agonists.
Muller P; Svensson TH; Carlsson A
Adv Biochem Psychopharmacol; 1980; 24():69-74. PubMed ID: 6105807
[No Abstract] [Full Text] [Related]
31. Evidence for a D1 dopamine receptor in the salivary glands of Amblyomma americanum (L.).
Schmidt SP; Essenberg RC; Sauer JR
J Cyclic Nucleotide Res; 1981; 7(6):375-84. PubMed ID: 7346526
[TBL] [Abstract][Full Text] [Related]
32. Receptors acting through adenylate cyclase in the CNS.
Wollemann M
Acta Physiol Acad Sci Hung; 1980; 55(4):299-304. PubMed ID: 6258390
[TBL] [Abstract][Full Text] [Related]
33. Relationship of calmodulin and dopaminergic activity in the striatum.
Gnegy ME
Fed Proc; 1982 May; 41(7):2273-7. PubMed ID: 6122610
[TBL] [Abstract][Full Text] [Related]
34. Substituted ergolines: potential antipsychotics with unique profile. II. Neurochemical characterization.
Auth F; Kiss B; Laszlovszky I; Lapis E
Pol J Pharmacol Pharm; 1988; 40(6):603-11. PubMed ID: 2479935
[TBL] [Abstract][Full Text] [Related]
35. Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and a comparison with dopamine receptor binding.
Seiler MP; Markstein R
Mol Pharmacol; 1982 Sep; 22(2):281-9. PubMed ID: 7144729
[No Abstract] [Full Text] [Related]
36. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs.
Baldessarini RJ; Tarsy D
Annu Rev Neurosci; 1980; 3():23-41. PubMed ID: 6106450
[No Abstract] [Full Text] [Related]
37. Dopamine-sensitive adenylyl cyclase: a receptor mechanism for dopamine.
Kebabian JW
Adv Biochem Psychopharmacol; 1978; 19():131-54. PubMed ID: 29445
[No Abstract] [Full Text] [Related]
38. Dopamine-receptor binding and adenylate-cyclase activity in mouse striatal tissue in the supersensitivity phase after neuroleptic treatment.
Hyttel J
Psychopharmacology (Berl); 1978 Dec; 59(3):211-6. PubMed ID: 32570
[No Abstract] [Full Text] [Related]
39. Blockade of the dopamine depressor response by molindone, a newly introduced neuroleptic.
Nandal NV; Mane VR; Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1980; 24(2):143-7. PubMed ID: 6103868
[TBL] [Abstract][Full Text] [Related]
40. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
